AOD-9604 Overview, Dosing & Safety | Peptide Database

AOD-9604 (hGH Fragment 176-191)

Modified hGH Fragment | Fat Loss Peptide

Community Research

Join others researching AOD-9604 — share findings, ask questions, and learn from real experiences

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

Molecular Data

Tyrosine

Position 1

Leucine

Position 2

Arginine

Position 3

Isoleucine

Position 4

Valine

Position 5

Glutamine

Position 6

Cysteine

Position 7

Position 8

Serine

Position 9

Position 10

Glutamic Acid

Position 11

Glycine

Position 12

Position 13

Position 14

Position 15

Phenylalanine

Position 16

Research Indications

Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.

Reduces fat synthesis and storage in adipose tissue.

Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.

Enhanced cartilage regeneration when combined with hyaluronic acid in osteoarthritis models.

Synergistic effects with hyaluronic acid for joint health.

Dosing Protocols

Subcutaneous injection is the standard route. Administer in the morning on an empty stomach, wait 30 minutes before eating for optimal results.

Fat loss - Standard

250-300mcg

Once daily (morning, fasted)

SubQ

Enhanced fat loss

400-500mcg

Joint support

250mcg

Once daily

Conservative start

200mcg

Reconstitution Instructions

Lyophilized AOD-9604 vial

Bacteriostatic water (BAC water)

Insulin syringes (0.5-1mL)

Alcohol swabs

Sterile work surface

1 Allow vial to reach room temperature (15-20 minutes)

2 Calculate required bacteriostatic water volume

3 Clean vial stopper with alcohol swab

4 Draw BAC water into syringe

5 Inject slowly down vial side (not directly onto powder)

6 Gently swirl until dissolved (never shake vigorously)

7 Store reconstituted solution at 2-8°C

8 Use within 28 days

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well-tolerated in clinical trials

Mild injection site reactions possible

No reported effects on blood glucose or insulin

Stop Signs - Discontinue if:

Severe injection site reactions or infection signs

Unusual swelling or persistent redness

Allergic reactions (rare)

Any concerning or unexpected symptoms

Contraindications

Pregnancy or breastfeeding

WADA prohibited - athletes subject to testing must avoid

Quality Checklist

Good Signs

White lyophilized powder with uniform appearance

Crystal clear solution without particles after reconstitution

Certificate of Analysis showing >98% purity by HPLC

Proper cold-chain shipping

Warning Signs

Not FDA approved as a therapeutic drug - research chemical only

WADA prohibited substance

Bad Signs

Discolored or clumped powder (yellow indicates degradation)

Cloudy solution after reconstitution

Collapsed or moisture-damaged appearance

Frequently Asked Questions

Does AOD-9604 cause blood sugar problems like full human growth hormone?

No. AOD-9604 is a modified hGH fragment that stimulates lipolysis without binding to the GH receptor or affecting glucose metabolism. Unlike full GH which causes hyperglycemia and insulin resistance, AOD-9604 does not increase IGF-1 levels or disrupt glucose homeostasis, making it metabolically safer.

How quickly will I see fat loss with AOD-9604?

Week 1-2 shows minimal noticeable effects as compound accumulates. Week 3-4 brings subtle body composition changes. Week 5-8 produces more noticeable fat loss especially with diet and exercise. Week 8-12 shows continued fat reduction and improved body composition. Total timeline is slower than GLP-1 agonists.

Can AOD-9604 be stacked with semaglutide or other weight loss peptides?

Yes. AOD-9604's lipolytic mechanism complements semaglutide's appetite suppression through completely different pathways. However, combination data is limited. Both are safe separately; combining requires monitoring for additive dehydration/GI effects common with semaglutide.

Is there any cartilage repair evidence for AOD-9604 in humans?

Animal studies show AOD-9604 combined with hyaluronic acid enhanced cartilage regeneration in osteoarthritis models. However, this is preclinical; human cartilage repair data doesn't exist. Joint health claims should be considered theoretical unless based on clinical trial data.

References

Both hGH and AOD-9604 reduced body weight gain, increased fat oxidation, and stimulated lipolysis in obese ob/ob mice after 14 days chronic IP administration, without affecting glucose metabolism.

Both hGH and AOD-9604 increased repressed beta-3 adrenergic receptor RNA expression in obese mice to levels comparable with lean mice. Effects abolished in beta-3-AR knockout mice, confirming pathway involvement.

Oral treatment of ob/ob mice with AOD-9401 for 30 days significantly reduced body weight gain and altered lipogenic and lipolytic activity in adipose tissue.

Characterized metabolic properties of AOD-9604 as a synthetic lipolytic domain of hGH with antilipogenic activity that does not interact with the GH receptor.

Intra-articular AOD-9604 injections enhanced cartilage regeneration in collagenase-induced osteoarthritis rabbit model. Combined AOD-9604 and hyaluronic acid injections were more effective than either alone.

Related Peptides

Different mechanisms; sometimes combined for comprehensive healing.

Different mechanisms; no known interactions.

Complementary weight loss mechanisms through different pathways.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.